Health
Thyroid Eye Disease
Landmark Approval: First-in-Class Drug Lumvoa Cleared for Thyroid Eye Disease, Treating Both Active and Chronic Stages
7 sources · 3d ago
Supplement Regulation
U.S. Physicians' Group Demands Congress Overhaul DSHEA, Require Pre-Market Approval for All Dietary Supplements
6 sources · 6d ago
Supplement Regulation
U.S. Physicians' Group Demands Congress Overhaul DSHEA, Require Pre-Market Approval for All Dietary Supplements
6 sources · 6d ago
More in Health
KRAS InhibitorsClinical Trial Results
Next-Generation KRAS Inhibitor Divarasib Shows Superiority Over Approved Drugs in Head-to-Head Lung Cancer Trial
Clinical Oncologists 40%Market Analysts 30%Drug Developers 30%
8 sources · 6d ago
Genetic MedicineBreakthrough Explainer
World's First Bespoke CRISPR Therapy Cures Infant With Rare Genetic Disease, Paving Way for 'N-of-1' Medicine
Clinical Innovators 40%Biotech & Manufacturing 35%Patient Advocates 25%
2 sources · 6d ago
Genetic MedicineBreakthrough Explainer
World's First Bespoke CRISPR Therapy Cures Infant With Rare Genetic Disease, Paving Way for 'N-of-1' Medicine
Clinical Innovators 40%Biotech & Manufacturing 35%Patient Advocates 25%
2 sources · 6d ago
Factlen ExplainerNutritional Science
Landmark Study Reveals Mediterranean Diet Activates Anti-Aging Mitochondrial Microproteins, Explaining Heart and Brain Benefits
Molecular Biologists 35%Clinical Dietitians 35%Precision Medicine Advocates 30%
7 sources · 6d ago
Factlen ExplainerNutritional Science
Landmark Study Reveals Mediterranean Diet Activates Anti-Aging Mitochondrial Microproteins, Explaining Heart and Brain Benefits
Molecular Biologists 35%Clinical Dietitians 35%Precision Medicine Advocates 30%
7 sources · 6d ago
Factlen ResearchCancer Interception
Landmark Trial: Preventative KRAS Vaccine Elicits Durable Immune Response in High-Risk Pancreatic Cancer Patients
Oncology Researchers 45%Clinical Skeptics 30%High-Risk Patients & Advocates 25%
7 sources · 6d ago
Factlen ResearchCancer Interception
Landmark Trial: Preventative KRAS Vaccine Elicits Durable Immune Response in High-Risk Pancreatic Cancer Patients
Oncology Researchers 45%Clinical Skeptics 30%High-Risk Patients & Advocates 25%
7 sources · 6d ago
Factlen ExplainerADHD Treatments
FDA Nears Approval for Centanafadine, a First-in-Class, Low-Abuse Potential ADHD Drug
Clinical Prescribers 40%Patient Advocates 35%Regulatory Specialists 25%
3 sources · 6d ago
Alzheimer's DiseaseExplainer
FDA Approves Kisunla to Slow Cognitive Decline in Early Alzheimer's Patients
Clinical Neurologists 44%Patient Advocates 33%Drug Safety Monitors 22%
3 sources · 6d ago
Biohacking LimitsMedical Explainer
Biohacker Bryan Johnson Diagnosed With 'Incurable' Autoimmune Gastritis
Medical Realists 45%Longevity Optimists 30%Autoimmune Patient Advocates 25%
3 sources · 6d ago
Biohacking LimitsMedical Explainer
Biohacker Bryan Johnson Diagnosed With 'Incurable' Autoimmune Gastritis
Medical Realists 45%Longevity Optimists 30%Autoimmune Patient Advocates 25%
3 sources · 6d ago
Cardiovascular HealthExplainer
FDA Approves First Oral PCSK9 Inhibitor to Treat High Cholesterol
Preventive Cardiologists 40%Patient Access Advocates 30%Clinical Skeptics 30%
6 sources · 7d ago
Cardiovascular HealthExplainer
FDA Approves First Oral PCSK9 Inhibitor to Treat High Cholesterol
Preventive Cardiologists 40%Patient Access Advocates 30%Clinical Skeptics 30%
6 sources · 7d ago
Factlen ExplainerSleep Medicine
Landmark Approval: Zepbound Becomes First Drug Treatment for Obstructive Sleep Apnea
Sleep Medicine Specialists 40%Patients with OSA 35%Healthcare Payers & Regulators 25%
5 sources · 7d ago
Prenatal CareExplainer
FDA Clears AI Ultrasound System That Significantly Improves Detection of Fetal Anomalies
Maternal-Fetal Specialists 40%Health Tech Developers 30%Patient Advocates 30%
3 sources · 7d ago
Menopause TreatmentsMedical Breakthrough
FDA Approves First-in-Class Non-Hormonal Drug, Elinzanetant, for Moderate to Severe Menopausal Hot Flashes
Women's Health Specialists 40%Breast Cancer Advocates 30%Pharmacological Researchers 30%
6 sources · 7d ago
Menopause TreatmentsMedical Breakthrough
FDA Approves First-in-Class Non-Hormonal Drug, Elinzanetant, for Moderate to Severe Menopausal Hot Flashes
Women's Health Specialists 40%Breast Cancer Advocates 30%Pharmacological Researchers 30%
6 sources · 7d ago
Longevity ScienceRegulatory Reversal
FDA Reverses Course on Drug Preclusion Rule, Reinstating NMN as a Legal Dietary Supplement
Supplement Industry Advocates 45%Consumer Safety Watchdogs 35%Pharmaceutical Developers 20%
7 sources · 8d ago
Longevity ScienceRegulatory Reversal
FDA Reverses Course on Drug Preclusion Rule, Reinstating NMN as a Legal Dietary Supplement
Supplement Industry Advocates 45%Consumer Safety Watchdogs 35%Pharmaceutical Developers 20%
7 sources · 8d ago